-
Market capitalisation of €1.1 billion
-
11th company listed on Euronext Paris in 2022
-
EUROAPI represents the largest Life Sciences listing in Europe in 2022 in terms of market capitalisation. EUROAPI is also the largest company in the pharmaceutical value chain to list on Euronext markets since 2012
Paris – 6 May 2022 – Euronext today congratulates EUROAPI, world leader in the Active Pharmaceutical Ingredients (API) market, on its listing on Compartment A of the regulated market in Paris (ticker code: EAPI).
EUROAPI originally formed part of the Sanofi Group, which will retain 30% of the company following the operation. EPIC Bpifrance, acting on behalf of the French State under the French Tech Sovereignty convention, has undertaken to acquire 12% of EUROAPI’s capital. EUROAPI is the world’s leading manufacturer of small molecules and the second largest manufacturer of APIs[1]. EUROAPI develops, manufactures and distributes a diversified portfolio of APIs as well as intermediates used in the formulation of medicines for human and veterinary use, both from originators and generics, through its activities “API Solutions” and “Contract Development and Manufacturing Organisation” (CDMO). The company operates six production sites in Europe and offers around 200 APIs to nearly 530 clients present in over 80 countries.
The listing of EUROAPI is part of the deployment of its strategy and its independence from Sanofi, which will remain EUROAPI’s long-term strategic partner. Listing on Euronext Paris will allow the company to reinforce its API development and manufacturing capacities in Europe, serving its customers on a global scale, in order to sustainably meet the needs of patients worldwide.
EUROAPI was listed through the admission to trading, through direct listing of the 94,026,888 shares making up its equity.
The issue price of EUROAPI shares was set at €12 per share. Market capitalisation was ca. €1.1 billion at the opening of the first trading day.
Karl Rotthier, CEO of EUROAPI, said: “This listing is an important step for EUROAPI. It aims to reinforce EUROAPI’s status as reference partner for all laboratories in the pharmaceutical and the biotechnology sectors, and to build upon its independence from Sanofi. This listing will allow EUROAPI to accelerate its strategy aimed at developing the Group’s activities as a CDMO, to reinforce its technological platforms, to leverage its presence in complex and highly differentiated APIs and to guarantee the Group’s operational efficiency. EUROAPI is convinced that it is today well positioned to capture future growth in the dynamic API market.”
Caption: Karl Rotthier, CEO of EUROAPI, and his team rang the bell during a ceremony this morning in the presence of Delphine d’Amarzit, CEO of Euronext Paris, to celebrate the listing of the company.
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. It is a leading player in active pharmaceutical ingredients with approximately 200 products in its portfolio, offering a large span of technologies, while developing innovative molecules through its Contract Development and Manufacturing Organisation (CDMO) activities. Taking action for health by enabling access to essential therapies inspires its 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. Find out more at www.euroapi.com
[1] Sources: estimate by EUROAPI based on market studies carried out by third parties based on data included in the annual reports published by the main industrial actors of the API sector, public databases (notably Capital IQ and Orbis) and interviews with market experts.